The development of gene therapies for the treatment of cancer has generally relied upon two strategies. The first is the expression of a therapeutic transgene from a replication-defective (RD) viral ...

Malignant melanoma is a highly aggressive tumor, which is the most rapidly growing cancer in incidence in the United States. 1 Although surgical removal of melanoma at an early stage is curative, once ...

Preclinical Data Shows the Robust Anti-Tumoral Activity of BT-001, Including Its Highly Effective and Safe Therapeutic Strategy of Targeting CLTA-4 LUND, SE / ACCESSWIRE / March 8, 2022 /BioInvent ...

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...

Oncolytic herpes simplex virus type I (HSV-1) vectors are promising therapeutic agents for cancer. Their efficacy depends on the extent of both intratumoral viral replication and induction of a host ...

Boosting of cellular and humoral immune responses to HPV16/18 antigens by VGX-3100: A follow-on phase I trial. A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 ...

LUND, Sweden and STRASBOURG, France, Nov 7, 2018 /PRNewswire/ -- BioInvent International AB (OMXS: BINV), focused on the discovery and development of novel and first-in-class immuno-regulatory ...

STRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against ...

The field of immuno-oncology is exciting for investors, patients and physicians, with a daily drum beat of new efforts being undertaken to battle cancer. Add Oncorus to that growing chorus. The ...

STRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and ...

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a ...

Preclinical proof-of-concept data published in the January 20, 2022 edition of the Journal for ImmunoTherapy of Cancer (JITC). Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that ...